Juvena Therapeutics
PrivateLast Round
Series B
Jan 12, 2026
Est. Valuation
$111M
Total Funding Raised
$131.16M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Juvena Therapeutics operates in Healthcare & Life Sciences and is based in Redwood City, California. Its latest recorded funding round was a Series B round in January 2026.
Juvena Therapeutics is a biotechnology company that develops AI-enabled regenerative biologics to restore tissue function and treat chronic and age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Juvena Therapeutics Comparables
Compare Juvena Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ARTHEx Biotech | 82% | |
| Secretome Therapeutics | 79% | |
| AI Proteins | 79% |
For institutional investors. Book with your work email.
Juvena Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 12, 2026 | ||||
| Series B | Jul 24, 2025 | ||||
| Series A | Nov 8, 2022 | ||||
| Grant | Feb 2, 2022 | ||||
| Grant | Aug 1, 2021 | ||||
Seed | Feb 26, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Juvena Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Horizons Ventures | Series B, Series A |
| NIH RADx | Grant |
| Plum Alley Investments | Series A |
| Intersect VC | Series A |
| Intersect Capital | Series A |
| Jefferson Life Sciences | Series B |
| California Institute for Regenerative Medicine | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 44% MoM.
- Jan 12, 2026
$34M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 17, 2026
On Aug 17th '26, Juvena Therapeutics, Inc. appoints Julie Anne Smith as Chief Executive Officer and member of its Board of Directors as JUV-161 enrolls subjects in a Phase 2a atrophy study.
- hiresAug 17, 2026
Juvena Therapeutics, Inc. appoints Julie Anne Smith as Chief Executive Officer and a member of its Board of Directors in California on Aug 17th '26, as lead biologic JUV-161 advances through Phase 2 clinical development.
For institutional investors. Book with your work email.
Juvena Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Juvena Therapeutics's valuation, stock price, and market status.
Is Juvena Therapeutics a public or private company?
Juvena Therapeutics is a private company.
What is the current stock price of Juvena Therapeutics?
Juvena Therapeutics is a private company, so its shares have no public market price. Caplight tracks Juvena Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Juvena Therapeutics worth (valuation)?
Juvena Therapeutics's valuation is estimated at $111.0M based on funding round data.
Can I buy Juvena Therapeutics stock?
Juvena Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Juvena Therapeutics's last funding round?
Juvena Therapeutics's most recent funding round was Series B on January 12, 2026.
Who are the main investors in Juvena Therapeutics?
Key investors in Juvena Therapeutics include Horizons Ventures, Jefferson Life Sciences, Mubadala Capital, Bison Ventures.
Will Juvena Therapeutics IPO soon?
No public IPO plans have been announced for Juvena Therapeutics.
How can I track Juvena Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Juvena Therapeutics's shares on secondary markets.